Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

P-011

Supelco

(+)-Propoxyphene solution

1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C22H29NO2
Numero CAS:
Peso molecolare:
339.47
Codice UNSPSC:
41116107
ID PubChem:
NACRES:
NA.24

Grado

certified reference material

Livello qualitativo

Forma fisica

liquid

Caratteristiche

Snap-N-Spike®/Snap-N-Shoot®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

drug control

Narcotic Licence Schedule A (Switzerland); estupefaciente (Spain); Decreto Lei 15/93: Tabela IA (Portugal)

Concentrazione

1.0 mg/mL in acetonitrile

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

forensics and toxicology

Formato

single component solution

Temperatura di conservazione

2-8°C

Stringa SMILE

CCC(=O)O[C@@](Cc1ccccc1)([C@H](C)CN(C)C)c2ccccc2

InChI

1S/C22H29NO2/c1-5-21(24)25-22(18(2)17-23(3)4,20-14-10-7-11-15-20)16-19-12-8-6-9-13-19/h6-15,18H,5,16-17H2,1-4H3/t18-,22+/m1/s1
XLMALTXPSGQGBX-GCJKJVERSA-N

Informazioni sul gene

human ... OPRM1(4988)

Descrizione generale

A certified Snap-N-Spike® solution standard suitable for propoxyphene testing methods by GC/MS or LC/MS in pain prescription monitoring, clinical toxicology, urine drug testing, or forensic analysis. Propoxyphene, also known as dextropropoxyphene, is an opioid analgesic drug intended for treatment of mild pain. In combination with either paracetamol or aspirin, dextropropoxyphene is sold under trade names including Darvocet-N® and Darvon®.

Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Darvocet-N is a registered trademark of AAIPharma LLC
Darvon is a registered trademark of Xanodyne Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Pittogrammi

FlameExclamation mark

Avvertenze

Danger

Indicazioni di pericolo

Classi di pericolo

Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Eye Irrit. 2 - Flam. Liq. 2

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

35.6 °F - closed cup

Punto d’infiammabilità (°C)

2 °C - closed cup


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Suicides involving co-proxamol fell dramatically after withdrawal in UK.
Zosia Kmietowicz
BMJ (Clinical research ed.), 344, e3255-e3255 (2012-05-11)
Margareeta Häkkinen et al.
Forensic science international, 222(1-3), 327-331 (2012-08-14)
There is a rising trend of fatal poisonings due to medicinal opioids in several countries. The present study evaluates the drug and alcohol findings as well as the cause and manner of death in opioid-related post-mortem cases in Finland from
W Stephen Waring et al.
Clinical toxicology (Philadelphia, Pa.), 49(6), 452-456 (2011-08-10)
The Medicines and Healthcare products Regulatory Authority (MHRA) is the government body with responsibility for regulating new and existing medicines and medical devices in the United Kingdom. The Yellow Card scheme is a well-established pharmacovigilance system that collects voluntary reports
Robert B Raffa et al.
Expert opinion on pharmacotherapy, 13(10), 1397-1409 (2012-05-10)
d-Propoxyphene, which was previously available in many single-agent and combination products, was recently voluntarily withdrawn from the US market following an FDA recommendation based partly on the concern that the risk associated with QT prolongation exceeded the clinical benefit of
Yatan Pal Singh Balhara et al.
Journal of opioid management, 8(1), 45-49 (2012-04-07)
In view of increasing safety concerns, there is a need to assess benefits of use of dextropropoxyphene as opioid substitution treatment, if any. This study aims at urinalysis-based comparative evaluation of pattern of use of dextropropoxyphene and buprenorphine among opioid-dependent

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.